AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03565653 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: dextrose
Study NCT04345874 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Children's environmental health technical assistance
Description: Participating family child care home providers in rural counties will be randomized to either the Nutrition Intervention (n=27), or an environmental health comparison group (n=27) that will receive an Integrated Pest Management and Green Cleaning intervention with the same format and visit frequency. Briefly, the Nutrition Technical Assistance Intervention and comparison group will consist of three encounters with our intervention team: two 60-90 minutes virtual one-on-one visits scheduled at the convenience of the family child care home provider and a 3-hour virtual group class session with other providers. Total contact time with intervention staff will be 6 hours. All participants will receive a toolkit. Providers will complete either intervention virtually over a period of three months.
Study NCT01899703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2330672
Description: GSK2330672 oral preserved solution 1.5mg/g will be supplied in amber glass bottles and as per randomization schedule subject will receive 45 mg BID from Day 1 to 3 and 90 mg BID from Day 4 to 14 of one of the two treatment periods.
Study NCT04632849 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GEM + CGM
Description: Participants follow the GEM guidebook for 4 months (1 month of intervention and 3 months of maintenance) while wearing a FitBit activity monitor and a Freestyle Libre 2 CGM to provide feedback about activity and blood glucose. The GEM guidebook covers Routine choices, Recovering from blood glucose excursions, Reducing blood glucose excursions, and Maintenance.
Study NCT01441544 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Variety of Active Videogames
Description: Thirty men and women, aged 18- to 35- years, recruited from the local area, with a normal body mass index (BMI) between 18.5 and 29.9 kg/m, will participate in two experimental sessions, VARIETY (playing the same active video game over 4 sessions) and NON-VARIETY (playing 4 different active video games over 4 sessions), with order of experimental sessions counterbalanced across participants.
Study NCT00584350 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydratation according LVEDP + NaHCO3
Description: Hydration with bolus of NaCl 0.9 to reach a LVEDP of 18 mmHg or more. This procedure is done while the patient is in the laboratory, with a catheter in the left ventricle.~At the same time, an infusion of a sodium bicarbonate solution (150 mEq/L) is started at a rate of 1 ml/kg/h (max 110 ml/h) for 7 hours.
Study NCT00584350 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: normal saline
Description: hydratation with normal saline (1 cc/kg/h; max 110 cc/h) starting at 8PM the day before the test and ending at 8PM the day of the test (24 hours total).
Study NCT00584350 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate
Description: hydratation with sodium bicarbonate (150 mEq/L) at 3 cc/kg/h (max 330 cc/h) for 1 hour before the test and then, to be continued at 1 cc/kg/h (max 110 cc/h) for 6 hours (total of 7 hours of hydratation).
Study NCT03980093 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Online medical education on the benefits of anti-hormonal medication, potential side effects, and how to manage them.
Study NCT03980093 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Online medical education on the benefits of anti-hormonal medication, potential side effects, and how to manage them.
Study NCT03980093 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Values
Description: An Acceptance and Commitment Therapy (ACT)-based intervention consisting of brief online sessions plus a visual cue-based intervention focused on personal values.
Study NCT00969722 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MAb-3F8
Study NCT00969722 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Subcutaneous Granulocyte Macrophage Colony Stimulating Factor (GM-CSF)
Study NCT00969722 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Subcutaneous Granulocyte Macrophage Colony Stimulating Factor (GM-CSF)
Study NCT00969722 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 13-cis-Retinoic Acid
Study NCT00793923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab and dexamethasone
Description: Combination therapy (group 1): same day combination therapy with 0.05cc dose intravitreal dexamethasone injection (10mg/ml vial) and a single 0.5 mg intravitreal ranibizumab injection
Study NCT00793923 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: intravitreal injection of 0.5 mg ranibizumab
Study NCT04595955 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CMyLife
Description: CMyLife is a digital patient platform for Patients With Chronic Myeloid Leukemia.
Study NCT00907738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: All patients will receive vorinostat at the same dose and schedule as they received in the base protocol until disease progression or unacceptable toxicity.
Study NCT03707093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADG106
Description: IV infusion over 60 minutes on Day 1 of each cycle, at doses of 0.03 mg/kg, 0.1 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg,10 mg/kg or 300mg flat dose depending on cohort at enrollment.
Study NCT03020511 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Ancient wheat flours
Description: Ancient wheat flours will be administered in open label for 30 days
Study NCT03580057 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breastfeeding promotion intervention
Description: Promotion (education, support and supervision) of breastfeeding by experienced breastfeeding consultants and midwife, in order to follow the Norwegian guideline of 6 months exclusive breastfeeding and partial breastfeeding for a year.
Study NCT03580057 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet and weight loss intervention
Description: 12-week program of dietary behavior modification treatment (LEVA-method by Bertz et al. Am J Clin Nutr 2012;96:698), leading to 6 kg weight loss (0.5 kg per week) and a healthier diet (less sugar, snacks, full fat products, more vegetables and fruit, smaller portion sizes). Weight is monitored by phone contact every second week. After 12 weeks, the women are followed up by e-mail contact for 9 additional months.
Study NCT00140465 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: after PCI
Study NCT01899703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo oral preserved solution will be supplied in amber glass bottles and as per randomization schedule subject will receive placebo BID from Day 1 to 14 of one of the two treatment periods. .
Study NCT01899703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid
Description: UDCA 250 mg will be supplied in capsule form. The subjects, who are taking UDCA at the time of Run-in-period, will be continued on the same total daily dose of drug but converted to a standardized formulation and a standardized dosing regimen administering the entire daily dose once daily in the evening before bedtime. Once daily dosing of UDCA will continue for the duration of the study.
Study NCT03971513 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trans abdominal plane
Description: Trans abdominal plane block is performed with ultra sound guidance.~1. - The high frequency probe is placed right to the umbilicus, and slips laterally to the side to block. It allows showing the three belts of larges muscles of abdomen (External Oblicum, internal oblicum, and transversal of the abdomen).~2. - When the needle is visualised in the plan separating the muscle internal oblicum and transversal of the abdomen, 20 ml of ropivacaïne 5mg/ml are injected after aspiration test. If in doubt, hydro localisation car be realised.
Study NCT00505492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 5 by vein once every 28 Days
Study NCT00505492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 40 mg/m\^2 by vein (IV) Weekly Over 4 Hours
Study NCT00505492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 135 mg/m\^2 by vein (IV) Once Every 28 Days
Study NCT02040064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: Oral tablet
Study NCT02040064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: IV
Study NCT04688944 — intervention group
Intervention type: OTHER
Intervention: observation
Description: observation the difference between two groups
Study NCT06742216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Monosialoganglioside
Description: Monosialoganglioside diluted with 0.9% normal saline 100ml, iv, daily for 12-14 days
Study NCT06742216 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo diluted with 0.9% normal saline 100ml, iv, daily for 12-14 days
Study NCT04236596 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Participants received a Neurostimulator, which was used to map the pudendal nerve
Description: Participants in study received neurostimulator at their pudendal nerve as part of their normal clinical care. This neurostimulator was used to map the nerve.
Study NCT00471107 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: DC brain polarization
Description: 0.08 mA/cm2
Study NCT00334750 — intervention group
Intervention type: OTHER
Intervention: There is no intervention in this study.
Description: This study is collecting information on the presence of risk factors in new diagnosed OH and OAG patients in Canada.
Study NCT02941731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIP1403
Description: Oseltamivir 6mg/mL
Study NCT02941731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP0919
Description: Oseltamivir phosphate 6mg/mL
Study NCT02132390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin
Study NCT02132390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toremifene
Study NCT03842709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexole Oral Tablet
Description: Initial dosage of 0.125 mg pramipexole daily, potentially titrated upward in 0.125 increments to a maximum of 0.5 mg daily, for 4 weeks.
Study NCT03842709 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of placebo
Study NCT01777633 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Palliative re-irradiation for progressive DIPG in children
Study NCT03873597 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tele-coaching + Usual Care
Description: The tele-coaching intervention will be delivered for 3 months following discharge from hospital. This consists of: 1) An interview discussing motivational issues, favourite daily activities and strategies to become more physically active; 2) a step counter 3) a smart phone with tele-coaching application providing activity goals (daily steps), feedback and educational tips on a daily basis. Patients' targets will be automatically revised on a weekly basis, based on performance in the preceding week; (4) a booklet containing home exercises; (5) weekly activity proposals; (6) tele-phone contacts triggered in the case of non-compliance, failure to transmit data or difficulty to progress.
Study NCT02734563 — intervention group
Intervention type: OTHER
Intervention: Collagen turnover
Description: Type IV and V collagen synthesis and breakdown
Study NCT04295902 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C-MAC indirect videolaryngoscope with blades Miller nr 0 and Miller nr 1.
Description: Tracheal intubation performed with the C-MAC indirect videolaryngoscope (Karl Storz, Tuttlingen, Germany) with blades Miller nr 0 and Miller nr 1.
Study NCT04295902 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Direct laryngoscope with blades Miller nr 0 and Miller nr 1.
Description: Tracheal intubation performed with a standard direct laryngoscope, with standard blades Miller nr 0 and Miller nr 1
Study NCT02978014 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ProSpare
Description: A novel rectal obturator (ProSpare) acting as a non-invasive daily on-line image guided tool, a rectal spacer and a prostate bed stabiliser
Study NCT00671151 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Theophylline
Description: Theophylline 100 mg bid for 3 months
Study NCT04975048 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Egg yolks
Description: Two egg yolks/day was designed for the study. However, uneven egg sizes during period 1 made the intervention unable to achieve the protocol's recommended cholesterol intake level, and the intervention was modified in period 2 to be 0.8 g egg yolk/day/kg body weight. This dosage was calculated by dividing the 35 g egg yolk with the lightest weight among the volunteers, which was 45 kg. This provides a more consistent cholesterol intake between persons as the egg yolk dosage is standardized for persons with different weights.
Study NCT04975048 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Egg yolks
Description: Two egg yolks/day was designed for the study. However, uneven egg sizes during period 1 made the intervention unable to achieve the protocol's recommended cholesterol intake level, and the intervention was modified in period 2 to be 0.8 g egg yolk/day/kg body weight. This dosage was calculated by dividing the 35 g egg yolk with the lightest weight among the volunteers, which was 45 kg. This provides a more consistent cholesterol intake between persons as the egg yolk dosage is standardized for persons with different weights.
Study NCT04975048 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Macronutrients equivalent control
Description: The macronutrients equivalent control group was served 42 g egg white cooked with 10 g olive oil, designed to best imitate the energy and macronutrients of 35 g egg yolk (energy 119 kcal, protein 5 g, fat 10 g, carbohydrate 1 g) since the average weight of two large egg yolk was presumed to be 35 g. As an egg yolk dose of 0.8 g egg yolk per kg body weight per day was served during the intervention period 2, the macronutrients equivalent control was likewise adjusted as follow: subjects who weighed less than 55 kg were served 51 g egg white cooked with 12 g olive oil, which is equivalent to 40 g egg yolk; those who weighed from 55 kg to 65 kg were served 61 g egg white cooked with 14 g olive oil, which is equivalent to 48 g egg yolk; and those who weighed more than 65 kg were served 71 g egg white cooked with 17 g olive oil, which is equivalent to 56 g egg yolk.
Study NCT04975048 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Macronutrients equivalent control
Description: The macronutrients equivalent control group was served 42 g egg white cooked with 10 g olive oil, designed to best imitate the energy and macronutrients of 35 g egg yolk (energy 119 kcal, protein 5 g, fat 10 g, carbohydrate 1 g) since the average weight of two large egg yolk was presumed to be 35 g. As an egg yolk dose of 0.8 g egg yolk per kg body weight per day was served during the intervention period 2, the macronutrients equivalent control was likewise adjusted as follow: subjects who weighed less than 55 kg were served 51 g egg white cooked with 12 g olive oil, which is equivalent to 40 g egg yolk; those who weighed from 55 kg to 65 kg were served 61 g egg white cooked with 14 g olive oil, which is equivalent to 48 g egg yolk; and those who weighed more than 65 kg were served 71 g egg white cooked with 17 g olive oil, which is equivalent to 56 g egg yolk.
Study NCT00704106 — intervention group
Intervention type: DRUG
Intervention: Entecavir
Description: 0.5 or 1 mg dose qd
Study NCT00893711 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus reuteri DSM 17938
Description: Lactobacillus reuteri is administered at a dose of 1.000.000.000 colony forming units (CFU) in V drops/day for 21 days
Study NCT00893711 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is administered in V drops once a day for 21 days. Placebo is inactive, similar to the studied treatment with the same package, taste, characteristics of colour and consistency.
Study NCT00893711 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: L.reuteri + Vit D
Study NCT00893711 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vit D placebo
Study NCT02286960 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Steroid
Description: A short 4 day course is administered to the first group of patients with voice disorders before the initiation of voice therapy.
Study NCT02286960 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Lactose Pills
Description: 4 day course 2 x 20mg per da
Study NCT00440401 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fibrinogen (human) + thrombin (human)
Study NCT00440401 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard haemostatic treatment in cardiovascular surgery
Description: Any haemostatic fleece material without additional active coagulation stimulating compounds (primarily Surgicel®)
Study NCT01938625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simeprevir
Description: Participants will receive 150 milligram capsule of simeprevir orally (by mouth) once daily with food for 24 weeks. In Part 1, if simeprevir pre-dose plasma concentration is greater than 7,300 nanogram per milliliter (ng/mL), participants will receive simeprevir 150 milligram capsule orally every other day to complete 24 weeks of treatment.
Study NCT01938625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Description: Participants will receive 60 milligram tablet of daclatasvir orally once daily for 24 weeks.
Study NCT01938625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Participants will receive 5 or 6 tablets of 200 milligram of ribavirin orally twice a day with food for 24 weeks.
Study NCT01938625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Participants will receive cyclosporine as one of the stable immunosuppressant therapy (no change in dose in the last month) for more than 3 months prior to the screening visit. Cyclosporine will be administered as per the manufacturer's prescribing information for 24 weeks.
Study NCT01938625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Participants will receive tacrolimus as one of the stable immunosuppressant therapy (no change in dose in the last month) for more than 3 months prior to the screening visit. Tacrolimus will be administered as per the manufacturer's prescribing information for 24 weeks.
Study NCT03591822 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: A : Systemic evaluation of the pain and mediation with the PARO therapeutic robot
Description: Each session with the PARO robot will encompasses the same four following steps (a) Meeting Paro (b) Proposing contact (c) Individually using Paro during the care (d) End of the exposure.
Study NCT03591822 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: B : Systemic evaluation of the pain
Description: A systematic evaluation of the pain
Study NCT02509546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 8-Chloroadenosine
Description: Given IV
Study NCT02509546 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02509546 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT04321863 — intervention group
Intervention type: OTHER
Intervention: Faecal calprotectin (FC)
Description: FC is a surrogate marker of neutrophil influx into the gut lumen. It accurately predicts mucosal healing (MH) at colonoscopy, and thus is already widely used in clinical practice in disease monitoring in CD patients (standard of care).
Study NCT04321863 — intervention group
Intervention type: OTHER
Intervention: quantitative Faecal Immunochemical Testing (qFIT)
Description: Stool test for haemoglobin. It has been shown to predict mucosal healing in Crohn's disease and ulcerative colitis. This study will compare the ability of qFIT and FC to predict flare in CD (qFIT is a cheaper, more stable test with a quicker turn-around time than FC, and is also less labour intensive for the lab).
Study NCT04321863 — intervention group
Intervention type: OTHER
Intervention: Serum and faecal zinc
Description: Blood sample for serum zinc will be taken at same time as routine (standard of care) monitoring bloods which include CRP - no additional venipuncture will be required. A single stool sample will be sufficient to measure FC (as outlines above) and faecal zinc. This study will compare the ability of serum/faecal zinc and CRP at predicting relapse in patients with quiescent (inactive) luminal (affecting the small and/or large bowel) CD.
Study NCT03485612 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Change of Optic Nerve Sheath Diameter
Description: In patients, the optic nerve sheath width (ONSD) examination will be performed twice: for the first time immediately after general anesthesia and again after surgery after placing the patient in a position on the back.
Study NCT01349738 — intervention group
Intervention type: DRUG
Intervention: Antibiotic
Description: Antibiotic (drug) sensitive to most recent culture for these subjects testing ASB positive and also experience Signs and symptoms of a UTI